S
CLDX icon

SignatureFD’s Celldex Therapeutics CLDX Stock Holding History

SignatureFD’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$13.4K Buy
423
+8
+2% +$218 ﹤0.01% 2383
2025
Q4 		$11.3K Hold
415
– – ﹤0.01% 2379
2025
Q3 		$10.7K Buy
415
+8
+2% +$185 ﹤0.01% 2386
2025
Q2 		$8.28K Sell
407
-154
-27% -$3K ﹤0.01% 2418
2025
Q1 		$10.2K Buy
561
+304
+118% +$6.79K ﹤0.01% 2349
2024
Q4 		$6.49K Buy
257
+124
+93% +$3.37K ﹤0.01% 2512
2024
Q3 		$4.52K Buy
133
+8
+6% +$305 ﹤0.01% 2608
2024
Q2 		$4.63K Buy
125
+6
+5% +$226 ﹤0.01% 2544
2024
Q1 		$4.99K Buy
119
+6
+5% +$246 ﹤0.01% 2542
2023
Q4 		$4.48K Buy
+113
New +$3.32K ﹤0.01% 2533
2023
Q1 		– Sell
-16
Closed -$713 – 3295
2022
Q4 		$713 Buy
+16
New +$571 ﹤0.01% 3043

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.58B AUM 138.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $57.5B AUM 55.25% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
EP
Eversept Partners New York $1.52B AUM 121.13% 1-Year Est. Return